- ►tripod.com [PDF] RA Whitmer, AJ Karter, K Yaffe, CP Quesenberry Jr, JV … - JAMA, 2009 - Am Med Assoc You are seeing this message because your Web browser does not support basic Web
standards. Find out more about why this message is appearing and what you can do to make
your experience on this site better. ... Add to CiteULike Add to Connotea Add to ... Cited by 13 - Related articles - All 3 versions
SR Heller - Diabetes, 2008 - Am Diabetes Assoc In this Perspectives article, I examine the evidence that underpins these interventions. It is beyond
the scope of this article to review the data for each potential intervention in detail, but the reader
is directed to the source where appropriate. The focus of this article is treatment of type 1 ... Cited by 7 - Related articles - All 5 versions
DM Kendall, RM Cuddihy, RM Bergenstal - European Journal of Internal …, 2009 - Elsevier Incretin-based therapies address the progressive nature of type 2 diabetes mellitus, not only
by addressing glucose control but also with weight-neutral (ie, dipeptidyl peptidase–4 inhibitors
sitagliptin and vildagliptin) and weight-reducing effects (ie, glucagonlike peptide–1 ... Cited by 4 - Related articles - All 38 versions
PE Cryer - Diabetologia, 2009 - Springer Page 1. FOR DEBATE Preventing hypoglycaemia: what is the appropriate glucose alert value?
PE Cryer Received: 16 October 2008 /Accepted: 21 October 2008 / Published online: 19
November 2008 # Springer-Verlag 2008 Keywords Glucose alert value . ... Cited by 2 - Related articles - All 2 versions
PJ O'Connell - Xenotransplantation, 2009 - interscience.wiley.com Abstract: Several clinical scenarios would justify trials of islet xenotransplantation, including islet
after kidney (IAK) transplantation and islet xenotransplantation for hypoglycemia
unawareness. In selecting a patient cohort, several factors unique to xenotransplant trials ... Related articles - All 2 versions
- ►diabetesjournals.org SA Amiel, PE Cryer - Diabetes, 2009 - Am Diabetes Assoc Hypoglycemia in diabetes is fundamentally the result of episodes of therapeutic hyperinsulinemia
caused by treatment with an insulin secretagogue or insulin. In general, the incidence of iatrogenic
hypoglycemia is a function of the degree of β-cell failure (1,2,4), and risk is predicted by ... Related articles - All 4 versions
LK Gilliam, IB Hirsch - Diabetes Technology & Therapeutics, 2009 - liebertonline.com Abstract The advent of commercially available real-time (rt) continuous glucose monitoring
(CGM) is revolutionizing diabetes care. This technology, which allows patients to view an approximation
of their blood glucose (BG) levels every 5 min, permits fine-tuning of a patient's glycemic ... Related articles - All 3 versions
SA Park, MK Park, JH Suk, MK Kim, YK Kim, IJ Kim, YH … - synapse.koreamed.org We measured the blood glucose level of type 2 diabetic patients who were treated with multiple
daily injections from January to July, 2008. The blood glucose levels were checked four times
a day for 14 days and were conversed according to the ADRR formula. The degree of ... Related articles - Cached - All 2 versions
